Q4 & FY22 Highlights

Robust financial performance Total Revenue (INR Cr.) CAGR: 25% 1581 1330 South Others India 7% 2% West Delhi & India NCR 2087 14% 34% Revenue by East Geography India (FY22) 15% FY20 FY21 FY22 • EBITDA*,PAT and Return on Net Worth (INR Cr./%) Normalised EBITDA* 365.6 227.6 Normalised PAT** 600.4 462.6 369.1 296.5 Rest of North India 28% FY20 FY21 FY22 EBITDA* Margin 27.5% 29.3% 28.8% Before ESOP & CSR Normalised 17.1% 18.7% 17.7% PAT Margin RONW 22.7% 25.4% 26.2% Growth driven primarily by increasing patient volumes and realization Increase in operating margin due to economies of scale and cost efficiencies * Normalised EBITDA excl. RSU, CSR **Normalised PBT & PAT excl. notional depreciation on consolidation of Suburban Classification: Restricted Note: Results includes Suburban financials wef 12th Nov 21. On transition from IGAAP to IND AS, revenue adjusted as per IND AS 115. 21 Dr Lal PathLabs

View entire presentation